Hawai'i's Medicaid program and those in 12 other states and the District of Columbia will share $116 million in a settlement with Cephalon Inc., which agreed to pay claims that it marketed three drugs for uses not approved by the Food and Drug Administration.

The U.S. Department of Justice yesterday announced Cephalon will enter a criminal plea and pay $425 million of claims. A lawsuit filed against Cephalon alleged the company marketed Gabitril, Actiq and Provigil for unapproved uses.